<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): March 16, 2009 (February 27, 2009)</B>

<P style="font-size: 24pt" align="center"><B>Lifevantage
Corporation<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Colorado</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-30489</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>90-0224471</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>11545 W. Bernardo Court,
Suite 301, San Diego, California <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>92127</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(858) 312-8000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;3.02 Unregistered Sales
of Equity Securities</B>

<P style="font-size: 10pt" align="justify">On March&nbsp;10, 2009, Lifevantage
Corporation (the &#8220;Company&#8221;) held the first closing of an offering
to accredited investors of shares of common stock and warrants to purchase
common stock (the &#8220;Offering&#8221;). To date, the Company has sold
3,925,000 shares of Common Stock of the Company at a purchase price of $0.20
per share and issued warrants exercisable for 3,925,000 shares of Common Stock
of the Company in the Offering, for aggregate gross proceeds of $785,000. The
warrants sold in the Offering have an exercise price of $0.50 per share and may
be exercised at any time following issuance during the three year exercise
period. The Company expects to close the remainder of the sales to accredited
investors in the Offering on or before March&nbsp;31, 2009.

<P style="font-size: 10pt" align="justify">The shares and warrants were offered
and sold in the Offering only to persons who meet the definition of
&#8220;accredited investor&#8221; set forth in Rule 501(a) of Regulation&nbsp;D
promulgated under the Securities Act of 1933, as amended, or to persons who are
not &#8220;U.S. persons&#8221; as defined in Regulation&nbsp;S under the
Securities Act, pursuant to exemptions from registration provided by
Rule&nbsp;506 of Regulation&nbsp;D of the Securities Act and Regulation&nbsp;S
of the Securities Act.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure</B>

<P style="font-size: 10pt" align="justify">On February&nbsp;27, 2009, Zrii, LLC
(&#8220;Zrii&#8221;) filed a&nbsp;complaint against Lifevantage Corporation
(the &#8220;Company&#8221;) and two former Zrii independent contractors in the
United States District Court for the Southern&nbsp;District of California. The
Company has retained outside counsel to respond to the claims of Zrii and
consider any potential counter claims by the Company. The Company&nbsp;believes
the claims of Zrii to be without merit and intends to defend the&nbsp;action
vigorously. The Company currently believes that the ultimate outcome of these
proceedings will not have a material adverse effect on the Company. However,
were an unfavorable ruling to occur, there exists the possibility of a material
adverse impact on the results of operations of the Company.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<P style="font-size: 10pt" align="justify">Date: March&nbsp;16, 2009

<P>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD colspan="2" align="left">LIFEVANTAGE CORPORATION</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left">By: </TD>
  <TD align="left" style="border-bottom: #000000 1px solid">/s/ Bradford K. Amman&nbsp;</TD>
</TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="left">Bradford K. Amman<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c82717e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8053}]
{"company-data": {"conformed-name": "Lifevantage Corp", "cik": "0000849146", "assigned-sic": "2834", "irs-number": "841097796", "state-of-incorporation": "CO", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-30489", "film-number": "09685715"}, "business-address": {"street1": "6400 SOUTH FIDDLER", "street2": "SUITE 1750", "city": "ENGLEWOOD", "state": "CO", "zip": "80111", "phone": "720-488-1711"}, "mail-address": {"street1": "6400 SOUTH FIDDLER", "street2": "SUITE 1750", "city": "ENGLEWOOD", "state": "CO", "zip": "80111"}, "former-company": [{"former-conformed-name": "LIFELINE THERAPEUTICS, INC.", "date-changed": "20041019"}, {"former-conformed-name": "YAAK RIVER RESOURCES INC", "date-changed": "19920703"}, {"former-conformed-name": "ANDRAPLEX CORP", "date-changed": "19920406"}]}
Form 8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 16, 2009 (February 27, 2009)
Lifevantage
Corporation
(Exact name of registrant as
specified in its charter)
Colorado
000-30489
90-0224471
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
11545 W. Bernardo Court,
Suite 301, San Diego, California
92127
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(858) 312-8000
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02 Unregistered Sales
of Equity Securities
On March 10, 2009, Lifevantage
Corporation (the "Company") held the first closing of an offering
to accredited investors of shares of common stock and warrants to purchase
common stock (the "Offering"). To date, the Company has sold
3,925,000 shares of Common Stock of the Company at a purchase price of $0.20
per share and issued warrants exercisable for 3,925,000 shares of Common Stock
of the Company in the Offering, for aggregate gross proceeds of $785,000. The
warrants sold in the Offering have an exercise price of $0.50 per share and may
be exercised at any time following issuance during the three year exercise
period. The Company expects to close the remainder of the sales to accredited
investors in the Offering on or before March 31, 2009.
The shares and warrants were offered
and sold in the Offering only to persons who meet the definition of
"accredited investor" set forth in Rule 501(a) of Regulation D
promulgated under the Securities Act of 1933, as amended, or to persons who are
not "U.S. persons" as defined in Regulation S under the
Securities Act, pursuant to exemptions from registration provided by
Rule 506 of Regulation D of the Securities Act and Regulation S
of the Securities Act.
Item 7.01 Regulation FD
Disclosure
On February 27, 2009, Zrii, LLC
("Zrii") filed a complaint against Lifevantage Corporation
(the "Company") and two former Zrii independent contractors in the
United States District Court for the Southern District of California. The
Company has retained outside counsel to respond to the claims of Zrii and
consider any potential counter claims by the Company. The Company believes
the claims of Zrii to be without merit and intends to defend the action
vigorously. The Company currently believes that the ultimate outcome of these
proceedings will not have a material adverse effect on the Company. However,
were an unfavorable ruling to occur, there exists the possibility of a material
adverse impact on the results of operations of the Company.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 16, 2009
LIFEVANTAGE CORPORATION
By:
/s/ Bradford K. Amman
Bradford K. Amman
Chief Financial Officer